Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2016 (2016), Article ID 5097364, 8 pages
http://dx.doi.org/10.1155/2016/5097364
Research Article

Highly Sensitive Micellar Enhanced Spectrofluorimetric Method for Determination of Mirtazapine in Tablets and Human Urine: Application to In Vitro Drug Release and Content Uniformity Test

1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
2Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt
3Department of Chemistry, Faculty of Science and Technology, El-Neelain University, P.O. Box 12702, 12702 Khartoum, Sudan
4Department of Aviation Medicine, King Abdulaziz Medical City, Ministry of National Guard, P.O. Box 22490, Riyadh 11426, Saudi Arabia

Received 5 April 2016; Revised 29 June 2016; Accepted 10 July 2016

Academic Editor: Ana M. García-Campaña

Copyright © 2016 Hany W. Darwish et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. K. Gillman, “A systematic review of the serotonergic effects of Mirtazapine in humans: implications for its dual action status,” Human Psychopharmacology, vol. 21, no. 2, pp. 117–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Goodnick, A. Puig, C. L. DeVane, and B. V. Freund, “Mirtazapine in major depression with comorbid generalized anxiety disorder,” Journal of Clinical Psychiatry, vol. 60, no. 7, pp. 446–448, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. L. M. Koran, N. N. Gamel, H. W. Choung, E. H. Smith, and E. N. Aboujaoude, “Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation,” The Journal of Clinical Psychiatry, vol. 66, no. 4, pp. 515–520, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Baldwin, I. M. Anderson, D. J. Nutt et al., “Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology,” Journal of Psychopharmacology, vol. 19, no. 6, pp. 567–596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. E. Kast and K. F. Foley, “Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects: Research in brief,” European Journal of Cancer Care, vol. 16, no. 4, pp. 351–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Mandrioli, L. Mercolini, N. Ghedini, C. Bartoletti, S. Fanali, and M. A. Raggi, “Determination of the antidepressant mirtazapine and its two main metabolites in human plasma by liquid chromatography with fluorescence detection,” Analytica Chimica Acta, vol. 556, no. 2, pp. 281–288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Karaşen and S. Altinöz, “Determination of mirtazapine in tablets by UV spectrophotometric and derivative spectrophotometric methods,” Journal of Pharmaceutical and Biomedical Analysis, vol. 24, no. 1, pp. 11–17, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Labat, P. Dallet, E. Kummer, and J. P. Dubost, “Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 2, pp. 365–371, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. R. M. Youssef, “Determination of mirtazapine in spiked human plasma and tablets by first derivative spectrofluorimetric method,” Saudi Pharmaceutical Journal, vol. 18, no. 1, pp. 45–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. Z.-D. Zhai, Y.-P. Shi, and T. Wang, “Development and validation of HPLC methods for enantioseparation of mirtazapine enantiomers at analytical and semipreparative scale using polysaccharide chiral stationary phases,” Analytica Chimica Acta, vol. 550, no. 1-2, pp. 123–129, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. F. J. M. de Santana and P. S. Bonato, “Enantioselective analysis of mirtazapine and its two major metabolites in human plasma by liquid chromatography-mass spectrometry after three-phase liquid-phase microextraction,” Analytica Chimica Acta, vol. 606, no. 1, pp. 80–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Hong, Y. Yao, S. Hong, and C. Lei, “LC-MS-MS analysis of mirtazapine in plasma, and determination of pharmacokinetic data for rats,” Chromatographia, vol. 68, no. 1-2, pp. 65–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Sánchez De La Torre, M. A. Martínez, and E. Almarza, “Determination of several psychiatric drugs in whole blood using capillary gas-liquid chromatography with nitrogen phosphorus detection: comparison of two solid phase extraction procedures,” Forensic Science International, vol. 155, no. 2-3, pp. 193–204, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Aturki, V. Scotti, G. D'Orazio, A. Rocco, M. A. Raggi, and S. Fanali, “Enantioselective separation of the novel antidepressant mirtazapine and its main metabolites by CEC,” Electrophoresis, vol. 28, no. 15, pp. 2717–2725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. S. Reddy and P. S. Devi, “Simultaneous determination of mirtazapine and its three main impurities by a high performance thin layer chromatography/densitometry method,” Journal of Liquid Chromatography and Related Technologies, vol. 31, no. 8, pp. 1204–1212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Salgado-Petinal, J. P. Lamas, C. Garcia-Jares, M. Llompart, and R. Cela, “Rapid screening of selective serotonin re-uptake inhibitors in urine samples using solid-phase microextraction gas chromatography-mass spectrometry,” Analytical and Bioanalytical Chemistry, vol. 382, no. 6, pp. 1351–1359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Adamowicz and M. Kała, “Simultaneous screening for and determination of 128 date-rape drugs in urine by gas chromatography—electron ionization-mass spectrometry,” Forensic Science International, vol. 198, no. 1–3, pp. 39–45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. F. J. M. De Santana, V. A. P. Jabor, E. J. Cesarino, V. L. Lanchote, and P. S. Bonato, “Enantioselective analysis of mirtazapine, demethylmirtazapine and 8-hydroxy mirtazapine in human urine after solid-phase microextraction,” Journal of Separation Science, vol. 33, no. 2, pp. 268–276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. F. J. M. de Santana, V. L. Lanchote, and P. S. Bonato, “Capillary electrophoretic chiral determination of mirtazapine and its main metabolites in human urine after enzymatic hydrolysis,” Electrophoresis, vol. 29, no. 18, pp. 3924–3932, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Rockville, “The United States Pharmacopoeia 30, the National Formulary 25 US Pharmacopeial Convention,” 2007.
  21. H. W. Darwish, A. S. Abdelhameed, A. H. Bakheit, and A. M. Alanazi, “A new method to determine the new C-Met inhibitor “Cabozantinib” in dosage form and human plasma via micelle-enhanced spectrofluorimetry,” RSC Advances, vol. 5, no. 51, pp. 40484–40490, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. I. Walash, F. Belal, M. M. Tolba, and M. I. Halawa, “Micelle-enhanced spectrofluorimetric determination of amlexanox in bioadhesive buccal tablets: application to content uniformity testing,” Luminescence, vol. 30, no. 6, pp. 823–829, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. J. B. Ghasemi and E. Zolfonoun, “Application of principal component analysis–multivariate adaptive regression splines for the simultaneous spectrofluorimetric determination of dialkyltins in micellar media,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 115, pp. 357–363, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. C. C. Wang, A. N. Masi, and L. Fernández, “On-line micellar-enhanced spectrofluorimetric determination of rhodamine dye in cosmetics,” Talanta, vol. 75, no. 1, pp. 135–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. N. A. Alarfaj and M. F. El-Tohamy, “Determination of the anti-viral drug Ribavirin in dosage forms via micelle-enhanced spectrofluorimetric method,” Luminescence, vol. 28, no. 2, pp. 190–194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. H. W. Darwish and A. H. Bakheit, “Micellar enhanced synchronous spectrofluorimetric method for determination of dasatinib in tablets, human plasma and urine: application to in vitro drug release and content uniformity test,” RSC Advances, vol. 5, no. 67, pp. 54471–54480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. H. W. Darwish, A. H. Bakheit, A. S. Abdelhameed, and A. S. Alkhairallah, “Micellar enhanced spectrofluorimetric method for the determination of ponatinib in human plasma and urine via cremophor RH 40 as sensing agent,” International Journal of Analytical Chemistry, vol. 2015, Article ID 210503, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. 2016, http://www.chemicalize.org/structure/#!mol=mirtazapine&source=fp.
  29. J. N. Miller and J. C. Miller, Statistics and Chemometrics for Analytical Chemistry, Pearson Education, 2005.
  30. ICH, “Validation of analytical procedures,” in Methodology (Q2AR1), International Conference on Harmonization, 1996, 2005. View at Google Scholar